New Study: Patient-Reported GLP-1 Symptoms Not Captured in Clinical Trials

A study published this month in Nature Health raises an important question for clinicians prescribing semaglutide and tirzepatide: are we capturing the full side-effect profile, or are there real-world symptoms that trial designs and current labeling underreport?

Researchers at the University of Pennsylvania used large language models to analyze 410,198 Reddit posts from 67,008 self-reported GLP-1 users, spanning May 2019 through June 2025. The findings suggest three categories of symptoms — menstrual irregularities, fatigue, and temperature dysregulation — appear at rates not well-reflected in current FDA labeling.

The implications are less about drug danger and more about what we should be asking our patients at follow-up visits.

Methodological Validation

Before getting to the novel findings, it's worth noting the validation step. The AI-analyzed rates for known GI side effects — nausea (36.9%), vomiting (16.3%), constipation (15.3%), diarrhea (12.6%) — closely matched published clinical trial data. This alignment suggests the method is capturing real signal rather than noise, which is what gives the novel findings clinical credibility.

Novel Patient-Reported Signals

Appropriate Clinical Caveats

The authors are explicit that findings are not causal. Reddit is an anonymous platform without verification. There's no placebo comparison group. And critically, rapid weight loss itself — from any cause — can produce many of these same symptoms independently of the medication.

Dr. Yuval Pinto, an obesity medicine physician at Johns Hopkins, articulated the appropriate skepticism in Everyday Health's coverage: we cannot determine from this data whether the drugs cause these symptoms, whether weight-loss-related physiology does, or whether Reddit's user population (younger, more male, US-based) generates reporting bias relative to the general GLP-1 population.

That said, the authors' framing is sound: this is a pharmacovigilance supplement, not a replacement. These are signals worth investigating in controlled follow-up studies, and meanwhile, worth asking patients about.

Clinical Implications

Update your intake and follow-up questions

Beyond the standard GI symptom screen, consider explicitly asking patients about fatigue, sleep quality, temperature sensitivity, and — for female patients — menstrual cycle changes. These may not be on standard intake forms but appear frequently enough in real-world data to warrant inquiry.

Don't dismiss unlisted symptoms

A patient reporting a symptom "not on the label" is not necessarily misattributing. They may be experiencing something we haven't systematically tracked. Appropriate workup (ruling out alternatives) is warranted before attributing to the drug — or dismissing.

Report to FAERS

If you identify symptoms that appear drug-associated, formal FDA reporting through MedWatch/FAERS is how these signals enter the pharmacovigilance pipeline. The Penn study's authors explicitly hope their findings encourage more systematic reporting.

Counsel patients on expectations

Patients whose symptoms get dismissed often turn to online communities for validation — where misinformation can also flourish. Acknowledging that symptom profiles are still being characterized, and that new patterns are emerging, builds trust and keeps patients engaged in their clinical care rather than self-managing through forums.

The Broader Methodological Shift

Beyond the specific GLP-1 findings, this study represents an emerging approach in pharmacovigilance: LLM-assisted analysis of unstructured patient-generated content at population scale. Expect more of it, particularly for rapidly-adopted drug classes where traditional surveillance lags real-world use. GLP-1s were an obvious first target; next-wave obesity therapeutics, peptide-based longevity interventions, and loosely regulated supplement categories are likely candidates.